Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Plans To Launch Melody Valve In The U.S. By April 2010

This article was originally published in The Gray Sheet

Executive Summary

Medtronic plans to launch its Melody transcatheter pulmonary heart valve by April 2010, pending humanitarian device exemption approval from FDA

You may also be interested in...



FDA OKs Medtronic's Melody HDE In First Transcatheter Valve Approval

Medtronic's Melody percutaneous pulmonary heart valve is the first transcatheter heart valve available in the U.S. following FDA humanitarian device exemption approval, announced Jan. 25

FDA OKs Medtronic's Melody HDE In First Transcatheter Valve Approval

Medtronic's Melody percutaneous pulmonary heart valve is the first transcatheter heart valve available in the U.S. following FDA humanitarian device exemption approval, announced Jan. 25

Medtronic Consolidates Units Into Two Broad Groups

Medtronic says it hopes to improve efficiency by restructuring its businesses into two groups

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel